跳至主要内容
临床试验/NCT01526616
NCT01526616已完成不适用

Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study

University Magna Graecia0 个研究点目标入组 56 人开始时间: 2010年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
56
主要终点
Metformin versus Metformin plus low-dose Spironolactone on metabolic parameters of Patients with Polycystic Ovary Syndrome: a randomized study

研究概览

简要总结

The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.

详细描述

In the present prospective, randomized study, we evaluated the efficacy of a combined therapy with metformin and low-dose spironolactone as compared to metformin alone on the clinical and endocrine-metabolic alterations of PCOS patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 35 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Overweight/obese patients with PCOS

排除标准

  • Other causes of hyperandrogenism and
  • Use of drugs including:
  • oral contraceptive
  • anti-hypertensive agents
  • anti-diabetic drugs
  • agents for weight loss

研究组 & 干预措施

Metformin

Active Comparator

850 mg/day twice a day

干预措施: Metformin (Drug)

Metformin plus spironolactone

Active Comparator

Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day

干预措施: Metformin plus Spironolactone (Drug)

结局指标

主要结局

Metformin versus Metformin plus low-dose Spironolactone on metabolic parameters of Patients with Polycystic Ovary Syndrome: a randomized study

时间窗: six months

We evaluated metabolic parameters across anthropometric parameters: height, weight, waist circumference, BMI, glycemia, lipid profile, blood count, coagulation parameters, hepatic and renal function indexes, OGTT and HOMA-IR. The diagnosis of MetS was established according to the ATPIII criteria

次要结局

  • Spironolactone versus Metformin plus spironolactone in hyperandrogenism in Polycystic Ovary Syndrome(six months)

研究者

发起方
University Magna Graecia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof Antonino Belfiore

Full Professor

University Magna Graecia

相似试验